Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis
Current Oncology · 2023
DOI: 10.3390/curroncol30010096 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Current Oncology, 2023. Verfasst von Jia Deng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Second Clinical College, Chongqing Medical University, Chongqing 400000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Thrombosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) may enhance the efficacy of treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, it remains unclear. We aim to evaluate the efficacy of TACE combined with TKIs.
Methods
A thorough literature search was performed on major databases since their inception until October 2022. Based on the eligibility criteria, eight studies (2103 patients) were included.
Results
Meta-analysis showed that TACE+sorafenib/apatinib had a better tumor response (objective response rate (ORR): RR = 4.85, 95% CI 2.68–8.75, disease control rate (DCR): RR = 3.23, 95% CI 1.88–5.56), and prolonged OS (HR = 0.50, 95%CI 0.42–0.60, p < 0.00001) than TACE alone. TACE+lenvatinib was stronger than TACE+sorafenib in ORR (60.7% vs. 38.9%) and TTP (HR = 0.61, 95% CI 0.43–0.86), whereas it was similar in DCR (96.4% vs. 96.3%) and OS (HR = 0.70 95% CI 0.46–1.05).
Conclusions
TACE plus sorafenib or apatinib was superior to TACE alone for hepatocellular carcinoma with PVTT; no significant advantage was found between TACE+lenvatinib and TACE+sorafenib, although TACE+lenvatinib performed better in terms of ORR and TTP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Clinical College, Chongqing Medical University, Chongqing 400000, China.
- Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China.
Zitieren
APA
Deng, J., Liao, Z., & Gao, J. (2023). Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Current Oncology. https://doi.org/10.3390/curroncol30010096
Vancouver
Deng J, Liao Z, Gao J. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Current Oncology. 2023. doi:10.3390/curroncol30010096
BibTeX
@article{Deng2023,
author = {Deng, Jia and Liao, Ziyue and Gao, Jian},
title = {Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30010096}
}
EUVIMED